In plain language
Across 1,680 congenital cardiac catheterization cases at 9 centres, updated patient radiation dose benchmarks were lower than earlier ones for six common procedures, with unchanged fluoroscopy time. Staff dose was not measured.
At a glance
- Type of study
- Original research, Prospective cohort study
- Who was studied
- Patients
- Size
- n = 1,680 cases
- Summary based on
- the abstract
What it found
Radiation doses were lowest for pulmonary valvuloplasty in infants and highest for transcatheter pulmonary valve implantation in patients over 15 years.
Key figures: median 59 mGy, dose-area product (DAP) 249 (age <1 yr) vs median 1835 mGy, DAP 17990 (age >15 yr)
Radiation doses decreased for all six procedures compared with the earlier retrospective benchmarks.
Dose reductions occurred without changes in median fluoroscopy time.
DAP per kilogram standardized outcomes across weights better than DAP alone.
Limits to keep in mind
Patient dose registry from 9 institutions with no staff dose measurement; abstract only, and the reasons for dose decline over time are not tested directly.
Related research summaries
- Fluoroscopy-minimization strategy for catheter ablation of Supraventricular Tachycardia by wOmen OPerators: the STOOP Multicentre Registry (2026, Prospective cohort study)
- Two Central Nervous System Tumors in One Catheter Lab: Time to Rethink Radiation Protection (2026, Retrospective cohort study)
- Radiation Awareness for EVAR in Hybrid Operating Room: An Instant Operator Risk Chart (2021, Dosimetry measurement study)
- Utilization of a Radiation Safety Time-Out Reduces Radiation Exposure During Electrophysiology Procedures (2019, Prospective cohort study)
- Completely nonfluoroscopic catheter ablation of left atrial arrhythmias and ventricular tachycardia (2018, Case report or series)
How this summary was made
ORSIF prepared this summary with AI assistance from the abstract of the paper. A program then checked that the passage supporting each finding appears word for word in that source. A person has not yet reviewed each summary, so read the original before relying on a number. ORSIF summarizes research and does not endorse any product or company. Report a problem with this summary.
Prepared November 3, 2026.